BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, April 9, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
4/5
cls
|
|
Aeterna
Zentaris Inc. (TSX:AEZ;
NASDAQ:AEZS)
|
Bloom
Burton
|
Philippa
Flint
|
Downgrade
|
Sell
(from hold)
|
-63%
|
$0.80
|
|
|
Rodman
|
Reni Benjamin
|
Downgrade
|
Market perform(from market outperform)
|
|
|
|
|
Summer
Street
|
Carol
Werther
|
Downgrade
|
Neutral
(from buy)
|
|
|
|
Flint
also lowered her target to $0.50 from $2.50 after perifosine missed the
primary endpoint in the Phase III X-PECT trial to treat refractory metastatic
colorectal cancer (mCRC) (see B16). Aeterna and partner Keryx
Biopharmaceuticals Inc. (NASDAQ:KERX) said they are analyzing the data to
determine next steps for the product, including whether to continue a Phase
III trial to treat multiple myeloma (MM). Flint said she expects the MM trial
to be terminated. Perifosine is an alkylphosphocholine modulator of the
phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB; AKT) and other signal
transduction pathways.
|
|
Benjamin
downgraded on the perifosine data, but said investors should not overlook the
multiple late-stage products in Aeterna's pipeline. He anticipates the
company will submit an NDA to FDA next half for Solorel macimorelin
(AEZS-130), an oral ghrelin-mimetic growth hormone secretagogue, to diagnose
adult growth hormone deficiency (AGHD). He also anticipates Aeterna will
begin a Phase III trial next half for AEZS-108, a doxorubicin
chemotherapeutic conjugated to luteinizing hormone-releasing hormone (LHRH)
receptor agonist, to treat endometrial cancer.
|
209
words displayed of
733
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]